Complement inhibitor therapy in atypical hemolytic uremic syndrome (aHUS): evaluating the economic impact of introducing eculizumab biosimilars in Germany. [PDF]
Kaufhold I +4 more
europepmc +1 more source
Global health and economic impact of expanding the WHO essential medicines list for psoriasis: a health economic modelling study. [PDF]
Ali F +12 more
europepmc +1 more source
Safety and Efficacy of Adalimumab Biosimilar in Psoriasis and Hidradenitis Suppurativa: <i>A Clinical Experience</i>. [PDF]
Najjar RH +5 more
europepmc +1 more source
Review of Quality Attributes and Analytical Methods Used for Comparative Analytical Assessment of Monoclonal Antibodies as Part of Successful Biosimilar Approvals in the United States and European Union. [PDF]
Aithal R +4 more
europepmc +1 more source
The biologics manufacturing patent notice challenge: a comparative examination. [PDF]
Jefferson OA, Rai A.
europepmc +1 more source
Population Pharmacokinetic Comparability of CT-P16 Versus EU-Avastin<sup>®</sup> and US-Avastin<sup>®</sup> in Healthy Subjects and Patients with Non-Squamous Non-Small Cell Lung Cancer. [PDF]
Kim T +6 more
europepmc +1 more source
Ten-Year Public Expenditure Savings Associated with TNF Inhibitor Biosimilars under Australia's Pharmaceutical Benefits Scheme. [PDF]
Yiu CH +4 more
europepmc +1 more source
Efficacy and Safety of the First Adalimumab Biosimilar in Chinese Children with Severe Plaque Psoriasis: The PISCES Study, a Multicenter Prospective Study. [PDF]
Huang Y +15 more
europepmc +1 more source

